The glycemic/metabolic responses to meal tolerance tests at breakfast, lunch and dinner, and effects of the mitiglinide/voglibose fixed-dose combination on postprandial profiles in Japanese patients with type 2 diabetes mellitus

Expert Opinion on Pharmacotherapy

Volumn 15, Issue 3, 2014, Pages 311-324

  Ono, Yuri ^a   Nakamura, Akinobu ^a,b   Yong Cho, Kyu ^a,b   Nomoto, Hiroshi ^a,b  

^a Yuri Ono Clinic Diabetes Internal Medicine   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Meal tolerance test; Mitiglinide; Mitiglinide voglibose combination; Postprandial glycemic excursions; Type 2 diabetes mellitus

Indexed keywords

C PEPTIDE; FATTY ACID; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; MITIGLINIDE; TRIACYLGLYCEROL; VOGLIBOSE;

AREA UNDER THE CURVE; CLINICAL TRIAL (TOPIC); DRUG EFFECT; FATTY ACID BLOOD LEVEL; FEMALE; GLUCAGON BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HUMAN; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; JAPANESE; MALE; MEAL; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; REVIEW;

AGED; BLOOD GLUCOSE; BREAKFAST; C-REACTIVE PROTEIN; DIABETES MELLITUS, TYPE 2; DRUG COMBINATIONS; FATTY ACIDS, NONESTERIFIED; FEMALE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INOSITOL; INSULIN; ISOINDOLES; LUNCH; MALE; MEALS; MIDDLE AGED; POSTPRANDIAL PERIOD; TRIGLYCERIDES;

EID: 84892713391     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2014.868437     Document Type: Review

References (28)

1. The DECODE-study group on behalf of the European Diabetes Epidemiology Group. Is fasting glucose sufficient to define diabetes? Epidemiological data from 20 European studies. Diabetes Epidemiology: collaborative analysis of Diagnostic Criteria in Europe. Diabetologia 1999;42:647-54.
2. Hanefeld M, Fischer S, Schmechel H, et al. Diabetes Intervention Study. Multiintervention trial in newly diagnosed NIDDM. Diabetes Care 1991;14:308-17
3. Tominaga M, Eguchi H, Manaka H, et al. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 1999;22:920-4
4. International diabetes federation. Guideline for management of postmeal glucose in diabetes. International Diabetes Federation; Brussels: 2011
5. Gao X. Multicentre, double-blind, randomized study of mitiglinide compared with nateglinide in type 2 diabetes mellitus patients in China. J Int Med Res 2009;37:812-21
6. Konya H, Miuchi M, Konishi K, et al. Pleiotropic effects of mitiglinide in type 2 diabetes mellitus. J Int Med Res 2009;37:1904-12
7. Li L, Yang M, Li Z, et al. Efficacy and safety of mitiglinide versus nateglinide in newly diagnose patients with type 2 diabetes mellitus: a randomized double blind trial. Diabetes Obes Metab 2012;14:187-9
8. Malaisse WJ. Mitiglinide: a rapid-and short-acting non-sulfonylurea insulinotropic agent for the treatment of type 2 diabetic patients. Expert Opin Pharmacother 2008;9:2691-8
9. Phillippe HM, Wargo KA. Mitiglinide for type 2 diabetes treatment. Expert Opin Pharmacother 2013;14:2133-44
10. Kawamori R, Tajima N, Iwamoto Y, et al. Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet 2009;373:1607-14
11. Kaku K, Tanaka K, Origasa H, et al. Concomitant effects of a rapid and short acting insulin secretagogue mitiglinide in type 2 diabetes patients with inadequate control of blood glucose with voglibose monotherapy-Phase II/III double blind comparative study. Jpn Pharmacol Ther 2007;35:S51-72; In Japanese
12. Katsuno T, Watanabe N, Nagai E, et al. Comparison of efficacy of concomitant administration of mitiglinide with voglibose and double dose of mitiglinide in patients with type 2 diabetes mellitus. J Diabetes Invest 2011;2:204-9
13. Inoue M. Tighter control of postprandial hyperglycemia with mitiglinide/voglibose fixed-dose combination in Japanese patients with type 2 diabetes mellitus. Expert Opin Pharmacother 2012;13:2257-68
14. Ono Y, Kameda H, Cho KY. Mitiglinide/voglibose fixed-dose combination improves postprandial glycemic excursions in Japanese patients with type 2 diabetes mellitus. Expert Opin Pharmacother 2013;14:361-70
15. Eto T, Inoue S, Kadowaki T. Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: a 4-week, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 2012;14:1040-6
16. Nonaka K, Tsubouchi H, Okuyama K, et al. Effects of once-daily sitagliptin on 24-h glucose control following 4 weeks of treatment in Japanese patients with type 2 diabetes mellitus. Horm Metab Res 2009;41:232-7
17. Rauch T, Graefe-Mody U, Deacon CF, et al. Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus. Diabetes Ther 2012;3:10
18. Yokoyama H, Kannno S, Ishimura I, et al. Miglitol increases the adiponectin level and decreases urinary albumin excretion in patients with type 2 diabetes mellitus. Metabolism 2007;56:1458-63
19. Dashora UK, Sibal L, Ashwell SG, et al. Insulin glargine in combination with nateglinide in people with type 2 diabetes: a randomized placebocontrolled trial. Diabet Med 2007;24:344-9
20. Hollander PA, Schwartz SL, Gatlin MR, et al. Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes. Diabetes Care 2001;24:983-8
21. Kodani N, Saisho Y, Tanaka K, et al. Effects of mitiglinide, a short-acting insulin secretagogue, on daily glycemic variability and oxidative stress markers in Japanese patients with type 2 diabetes mellitus. Clin Drug Investig 2013;33:563-70
22. Yoshino G, Tominaga M, Hirano T, et al. The test meal A: a pilot model for the international standard of test meal for an assessment of both postprandial hyperglycemia and hyperlipidemia. J Jpn Diabetes Soc 2006;49:361-71
23. Tsujino D, Nishimura R, Taki K, et al. Comparing the efficacy of alphaglucosidase inhibitors in suppressing postprandial hyperglycemia using continuous glucose monitoring: a pilot study-the MAJOR study. Diabetes Technol Ther 2011;13:303-8
24. Monnier L, Colette C, Dunseath GJ, et al. The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care 2007;30:263-9.
25. Assaloni R, Da Ros R, Quagliaro L, et al. Effects of S21403 (mitiglinide) on postprandial generation of oxidative stress and inflammation in type 2 diabetic patients. Diabetologia 2005;48:1919-24
26. Satoh N, Shimatsu A, Yamada K, et al. An alpha-glucosidase inhibitor, voglibose, reduces oxidative stress markers and soluble intercellular adhesion molecule 1 in obese type 2 diabetic patients. Metabolism 2006;55:786-93
27. Iovine C, Vaccaro O, Gentile A, et al. Post-prandial triglyceride profile in a population-based sample of type 2 diabetic patients. Diabetologia 2004;47:19-22
28. Nordestgaard BG, Benn M, Schnohr P, et al. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007;298:299-308